证券代码：688687 证券简称：凯因科技 公告编号：2023-046 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2023年第三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2023 年 11 月 28 日（星期二）下午 15:00-16:00。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/）。 会议召开方式：上证路演中心网络互动。 投资者可于 2023 年 11 月 21 日（星期二）至 11 月 27 日(星期一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@kawin.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 (一) 会议召开时间：2023年11月28日(星期二)下午15:00-16:00 (二) 会议召开地点：上证路演中心（https://roadshow.sseinfo.com/） 北京 ...

证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 投资者关系活动记录表 ...

证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 投资者关系活动记录表 ...

Financial Performance - The company's operating revenue for Q3 2023 reached ¥433,587,235.35, representing a year-on-year increase of 26.10%[4] - The net profit attributable to shareholders for Q3 2023 was ¥51,896,370.91, a significant increase of 66.56% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥53,021,525.05, up 54.70% year-on-year[4] - The basic earnings per share for Q3 2023 was ¥0.310, reflecting an increase of 68.48% compared to the previous year[5] - Operating profit for the third quarter was ¥133,104,736.27, up from ¥83,877,951.46 in the previous year, reflecting a significant growth[20] - Net profit for the first three quarters of 2023 was ¥103,002,929.53, compared to ¥65,367,688.01 in the same period last year, indicating a 57.5% increase[20] - Total revenue for the first three quarters of 2023 reached ¥1,002,328,483.55, a 19.8% increase from ¥836,731,606.49 in the same period of 2022[19] - Total comprehensive income for Q3 2023 was ¥104,966,593.91, up from ¥68,943,923.00 in Q3 2022, representing an increase of approximately 52%[21] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥2,315,906,842.31, an increase of 4.81% from the end of the previous year[5] - Total assets increased to ¥2,315,906,842.31 from ¥2,209,724,972.77, showing a growth of approximately 4.8%[17] - Total liabilities rose to ¥565,360,444.41, up from ¥527,934,808.32, representing a 7.1% increase[17] - The total equity attributable to shareholders at the end of the reporting period was ¥1,727,247,783.00, an increase of 3.09% from the previous year[5] - The company's total equity increased to ¥1,750,546,397.90 from ¥1,681,790,164.45, reflecting a growth of 4.1%[17] Cash Flow - The net cash flow from operating activities for the year-to-date period decreased by 65.38%, primarily due to increased procurement payments[8] - Cash flow from operating activities for the first three quarters of 2023 was ¥34,283,548.58, down from ¥99,030,532.23 in the same period of 2022, indicating a decline of approximately 65%[22] - The company reported cash and cash equivalents of ¥866,918,251.56 at the end of Q3 2023, compared to ¥580,619,199.10 at the end of Q3 2022, indicating a year-over-year increase of about 49%[23] - The company recorded a net increase in cash and cash equivalents of ¥146,332,312.30 in Q3 2023, contrasting with a net decrease of ¥572,651,999.32 in Q3 2022[23] Research and Development - Research and development expenses for Q3 2023 totaled ¥30,415,977.66, accounting for 7.01% of operating revenue, a decrease of 2.06 percentage points year-on-year[5] - Research and development expenses for the third quarter were ¥68,195,871.59, slightly down from ¥69,860,306.50 in the previous year[20] Shareholder Information - The company reported a total of 7,787 common shareholders at the end of the reporting period[10] Inventory and Receivables - Accounts receivable increased to ¥412,236,738.69 from ¥333,297,094.96, representing a growth of about 23.7% year-over-year[14] - The company's inventory increased to ¥163,037,058.74 from ¥148,810,966.21, marking a growth of about 9.5%[14] Financial Activities - The total cash outflow from financing activities was ¥60,881,120.79 in Q3 2023, down from ¥84,689,261.86 in Q3 2022, showing a decrease of approximately 28%[23] - The company reported a financial expense of -¥14,028,664.05, an improvement from -¥17,564,755.54 in the previous year[20] Other Information - The company has expanded its sales channels and launched new core products, contributing to revenue and profit growth[8] - The company has not disclosed any new product or technology developments during the quarter[13] - There are no significant mergers or acquisitions reported in the current quarter[13] - The company has not provided specific future guidance or market expansion strategies in the current report[13] - The company did not apply new accounting standards for the year 2023, maintaining consistency in financial reporting[24]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 证券代码：688687 证券简称：凯因科技 公告编号：2023-044 北京凯因科技股份有限公司 第五届董事会第十九次会议决议公告 公司2023年第三季度报告的编制符合相关法律法规及《公司章程》等内部规 章制度的规定。2023年第三季度报告真实、准确、完整地反映了公司的财务状况、 经营成果和现金流量状况等事项。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 具体内容详见公司登载于上海证券交易所网站（www.sse.com.cn）上的《北 京凯因科技股份有限公司2023年第三季度报告》。 特此公告。 北京凯因科技股份有限公司董事会 2023 年 10 月 27 日 北京凯因科技股份有限公司（以下简称"公司"）第五届董事会第十九次会 议于2023年10月26日在公司会议室以现场结合通讯表决方式召开，会议通知于 2023年10月16日以电子邮件、电话方式送达。会议应出席董事9名，实际出席董 事9名。会议由董事长周德胜先生主持。公司监事、高级管理人员列 ...

证券代码：688687 证券简称：凯因科技 公告编号：2023-045 北京凯因科技股份有限公司 第五届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京凯因科技股份有限公司（以下简称"公司"）第五届监事会第十三次会 议于2023年10月26日以现场结合通讯表决方式在公司会议室召开，会议通知于 2023年10月16日以电子邮件、电话方式送达。会议应出席监事3名，实际出席监 事3名。会议由监事会主席吴珂女士主持。会议的召集、召开符合《公司法》和 《公司章程》的相关规定。 二、监事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一）审议通过了《关于公司2023年第三季度报告的议案》 经审核，监事会认为董事会编制和审核公司 2023 年第三季度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公 司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 表决结果：3票同意，0票反对，0票弃权。 具体内容详见公司登载于上海证券交易所网 ...

证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 投资者关系活动记录表 ...

海通证券股份有限公司 一、2023 年半年度保荐机构持续督导工作情况 1 | 项 目 | 工作内容 | | --- | --- | | 作开始前，与上市公司或相关当事人签署持续 | 明确了双方在持续督导期间的权利和义务，并 | | 督导协议，明确双方在持续督导期间的权利义 | 已报上海证券交易所备案。本持续督导期间， | | 务，并报上海证券交易所备案。持续督导期间， | 未发生对协议内容做出修改或终止协议的情 | | 协议相关方对协议内容做出修改的，应于修改 | 况。 | | 后五个交易日内报上海证券交易所备案。终止 | | | 协议的，协议相关方应自终止之日起五个交易 | | | 日内向上海证券交易所报告，并说明原因。 | | | 3、持续督导期间，按照有关规定对上市公司 | 本持续督导期间，上市公司未发生需公开发表 | | 违法违规事项公开发表声明的，应于披露前向 | 声明的违法违规事项。 | | 上海证券交易所报告，并经审核后予以披露。 | | | 4、持续督导期间，上市公司或相关当事人出 | | | 现违法违规、违背承诺等事项的，应自发现或 | 本持续督导期间，上市公司及相关当事人未出 | | 应当 ...

证券代码：688687 证券简称：凯因科技 公告编号：2023-043 北京凯因科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京凯因科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 25 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上 半年度经营成果、财务状况，公司计划于 2023 年 09 月 13 日下午 15:00-16:00 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2023年半年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 (二) 会议召开地点：上证路演中心（http://roadshow.sseinfo.com/） (三) 会议召开方式：上证路演中心网络互动 三、参加人员 董事长兼总裁：周德胜先生 董事会秘书：赫 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2023 was approximately ¥568.74 million, representing a 15.39% increase compared to ¥492.89 million in the same period last year[24]. - The net profit attributable to shareholders for the same period was approximately ¥38.36 million, a 3.01% increase from ¥37.24 million year-on-year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 68.18% to approximately ¥41.80 million from ¥24.85 million in the previous year[24]. - The basic earnings per share for the first half of 2023 was ¥0.229, up 4.57% from ¥0.219 in the same period last year[23]. - The company reported a significant increase in revenue, achieving a total of $X million for the first half of 2023, representing a Y% growth compared to the same period last year[117]. - The company reported a total revenue of 1.5 billion, representing a year-over-year increase of 15%[120]. - The net profit for the first half of 2023 was reported at 170,908,422.0, indicating a significant increase from the previous year[192]. User Growth - User data showed a growth in active users by 15%, reaching 1.2 million users by the end of June 2023[1]. - User data showed a growth of 20% in active users, reaching a total of 5 million users[114]. - User data showed an increase in active users to 10 million, up from 8 million in the previous period, marking a growth of 25%[121]. Research and Development - Research and development expenses increased by 30%, totaling 150 million RMB, reflecting the company's commitment to innovation[1]. - The company's R&D expenditure as a percentage of operating revenue decreased to 9.87%, down 4.73 percentage points from 14.60% in the previous year[23]. - The company applied for 13 invention patents in the first half of 2023, with a total of 154 applications and 51 granted patents to date[39]. - Total R&D investment for the period was CNY 56.14 million, a decrease of 22% compared to the previous year, with R&D expenses accounting for 9.87% of revenue[41]. - The company has a total of 125 R&D personnel, which is 16.53% of the total workforce, up from 14.12% in the previous year[54]. - The average salary of R&D personnel increased to 16.79 thousand RMB, compared to 14.90 thousand RMB in the previous year[54]. - Research and development expenses for the first half of 2023 were ¥43,833,264.51, down from ¥51,820,640.26, a decline of 15.4%[168]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[113]. - Market expansion strategies include potential acquisitions, with a focus on integrating F companies to strengthen market position[118]. - The company plans to enhance its digital marketing strategy, aiming for a 30% increase in online sales[120]. Product Development - New product launches included two innovative drug candidates, with expected market entry in Q4 2023, projected to generate an additional 200 million RMB in revenue[1]. - The company is focusing on the development of innovative drugs for hepatitis B, with a pipeline aimed at functional cure combinations[52]. - The company has developed a new long-acting interferon α-2 injection, which has shown better efficacy and ease of use for treating HEHE[10]. - The company’s product lineup includes antiviral and immune regulation drugs, with several products listed in the National Basic Medical Insurance directory[29]. - New product launches are expected to contribute an additional C million in revenue, with anticipated market expansion into D regions[118]. Financial Position - The total assets at the end of the reporting period were approximately ¥2.15 billion, a decrease of 2.65% from ¥2.21 billion at the end of the previous year[24]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥1.68 billion, a slight decrease of 0.09% from ¥1.67 billion at the end of the previous year[24]. - The company's total liabilities decreased to ¥370,294,372.15 from ¥434,161,604.09, a reduction of approximately 14.7%[166]. - The company's total equity attributable to shareholders was CNY 1,673,967,443.07, slightly down from CNY 1,675,556,748.68, a decrease of approximately 0.1%[162]. - The total equity of the company at the end of the reporting period is CNY 1,706,789,187.8, with a capital reserve of CNY 1,248,297,781.09 and retained earnings of CNY 353,628,242.16[196]. Governance and Compliance - The company has no significant non-operating fund occupation by controlling shareholders or related parties[1]. - There were no violations of decision-making procedures regarding external guarantees during the reporting period[1]. - The board of directors confirmed that all members attended the board meeting, ensuring governance compliance[1]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[124]. - The company has not engaged in any major guarantees or violations during the reporting period, reflecting sound governance practices[124]. Risks and Challenges - The report emphasizes the importance of risk factors and forward-looking statements, advising investors to be cautious[1]. - The company faces risks related to new drug development, including potential clinical trial failures and regulatory changes that could impact expected revenues[65]. - The company is at risk of losing core technical personnel, which could affect its innovation capabilities and market competitiveness[67]. - The company is involved in a patent infringement lawsuit with Gilead, which could impact the production and sales of its product Sofosbuvir if the court rules against it[72]. Environmental Responsibility - The company has invested 35.65 million yuan in environmental protection during the reporting period[103]. - The wastewater treatment facility has a processing capacity of 300 tons per day and is operating normally[105]. - The company has implemented air pollution control measures with a volatile organic compound treatment capacity of 20,000 cubic meters per hour, which is functioning properly[105]. - The company is classified as a key pollutant discharge unit in Beijing and complies with relevant pollution discharge standards[104]. - The company conducts regular environmental monitoring through a third-party qualified testing agency, ensuring compliance with environmental regulations[107].